Lupus Nephritis - Drug Pipeline Landscape, 2023
Lupus Nephritis is an autoimmune kidney disease caused by systemic lupus erythematosus (SLE). It is a type of glomerulonephritis where autoantibodies affect the structures of glomeruli which results in inflammation and decreased kidney output.
Lupus Nephritis is mainly of 6 types, following minimal mesangial glomerulonephritis, mesangial proliferative glomerulonephritis, focal glomerulonephritis, diffuse proliferative nephritis, membranous glomerulonephritis and advanced sclerosing lupus nephritis.
The main cause of the lupus nephritis is the genetic predisposition, and environmental triggers interplay. The other cause is damage of the kidneys and harming their ability to filter out waste due to the immune system proteins caused by systemic lupus.
General signs and symptoms of lupus nephritis is high blood pressure, edema, malar rash, foamy urine, fatigue, joint pain, fever, blood in urine, protein in urine and impaired kidney function.
The diagnosis of lupus nephritis includes blood tests, urinalysis, X-rays, ultrasound scans of the kidneys and kidney biopsy.
The main goal in the treatment of lupus nephritis is to reduce symptoms, maintain remission, and avoiding the need for dialysis. The drug regimen includes anti-hypertensive agents, immunosuppressive agents, corticosteroids, and diuretics.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Lupus Nephritis treatment such as Mizoribine, anifrolumab, atacicept, and others. Key players involved in the development of therapies to treat Lupus Nephritis are Novartis AG, Alexion Pharmaceuticals, and Johnson & Johnson and others. One drug is under late-stage pre-registration stage, 5 drugs are in Phase III clinical trials and eleven drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0, and preclinical stages of development. In Aug 2022, Vera Therapeutics reported financial results in which it mentioned that it has completed enrolment of atacicept Phase IIb trial.
Report Highlights
Global Insight Service's, Lupus Nephritis - Drug Pipeline Landscape, 2023 report provides an overview of the Lupus nephritis pipeline drugs. This report covers detailed insights on Lupus Nephritis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Lupus Nephritis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
- 1. Introduction
- 1.1 Lupus Nephritis - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Lupus Nephritis
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Lupus Nephritis - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late Stage Drugs – Pre-Registration
- 5.1.1 Mizoribine
- 5.2 Clinical Stage Drugs – Phase III
- 5.2.1 Anifrolumab
- 5.2.2 Atacicept
- 5.2.3 Ianalumab
- 5.2.4 Obinutuzumab
- 5.2.5 Secukinumab
- 5.3 Clinical Stage Drugs – Phase II
- 5.3.1 BI 655064
- 5.3.2 CFZ533
- 5.3.3 CS20AT04
- 5.3.4 Daxdilimab
- 5.3.5 Guselkumab
- 5.3.6 Iptacopan
- 5.3.7 Narsoplimab
- 5.3.8 Ravulizumab
- 5.3.9 Vemircopan
- 5.3.10 Zanubrutinib
- 5.3.11 Zetomipzomib
- 5.4 Clinical Stage Drugs – Phase I
- 5.4.1 ANX009
- 5.4.2 CS20AT04
- 5.4.2 Itolizumab
- 5.4.3 Mesenchymal stromal cells
- 5.4.4 Nipocalimab
- 5.4.5 Vunakizumab
- 5.5 Clinical Stage Drugs – Phase 0
- 5.5.1 CD19/BCMA CAR T-cells
- 5.6 Early Stage Drugs – Preclinical
- 5.5.1 Ampion
- 5.5.2 Avacopan
- 5.5.3 CK0808
- 5.5.4 IBL 101
- 5.5.5 NTR-441
- 5.5.6 RHX-317
- 5.5.7 SER-101
- 5.5.8 Tegoprubart
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Alexion Pharmaceuticals
- 9.2 Ampio Pharmaceuticals Inc
- 9.3 Annexon Inc
- 9.4 Asahi Kasei Pharma Corp
- 9.5 AstraZeneca
- 9.6 BeiGene Inc
- 9.7 Boehringer Ingelheim Pharmaceuticals, Inc
- 9.8 Cellenkos Inc
- 9.9 ChemoCentryx
- 9.10 Corestem, Inc
- 9.11 Eledon Pharmaceuticals Inc
- 9.12 Equillium Bio
- 9.13 F. Hoffmann-La Roche Ltd
- 9.14 Horizon Therapeutics plc
- 9.15 Inflection Biosciences, Inc
- 9.16 Johnson & Johnson
- 9.17 Kezar Life Sciences Inc
- 9.18 Neutrolis
- 9.19 Novartis AG
- 9.20 Omeros Corp
- 9.21 Red de Terapia Celular
- 9.22 Rheos Medicines
- 9.23 Serenity Bioworks
- 9.24 Suzhou Suncadia Biopharmaceuticals Co Ltd
- 9.24 Vera Therapeutics Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2.1 Clinical Trial Details – Anifrolumab/AstraZeneca
- Table 2.2 Clinical Trial Details – Ianalumab/Novartis Pharmaceuticals
- Table 2.3 Clinical Trial Details – Secukinumab/Novartis Pharmaceuticals
- Table 2.4 Clinical Trial Details – BI 655064/Boehringer Ingelheim
- Table 2.5 Clinical Trial Details – CFZ533 /Novartis Pharmaceuticals
- Table 2.6 Clinical Trial Details – Guselkumab /Johnson & Johnson
- Table 2.7 Clinical Trial Details – Iptacopan /Novartis Pharmaceuticals
- Table 2.8 Clinical Trial Details – Mesenchymal stromal cells /Red de Terapia Celular
- Table 2.9 Clinical Trial Details – Mycophenolate Mofetil/Genentech, Inc
- Table 2.10 Clinical Trial Details – Obinutuzumab /F. Hoffmann-La Roche
- Table 2.11 Clinical Trial Details – Ravulizumab /Alexion Pharmaceuticals
- Table 2.12 Clinical Trial Details – Vemircopan /Alexion Pharmaceuticals
- Table 2.13 Clinical Trial Details – Vunakizumab /Jiangsu Hengrui Pharmaceuticals Co., Ltd
- Table 2.14 Clinical Trial Details – Zanubrutinib /BeiGene, Inc
- Table 2.15 Clinical Trial Details – Zetomipzomib/Kezar Life Sciences Inc
- Table 2.16 Clinical Trial Details – CS20AT04 /Corestem Inc
- Table 2.17 Clinical Trial Details – Itolizumab/Equillium Bio
- Table 2.18 Clinical Trial Details – Nipocalimab/Johnson & Johnson
- Table 2.29 Clinical Trial Details – CD19/BCMA CAR T-cells/Shanghai YaKe Biotechnology
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Lupus Nephritis, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Lupus Nephritis, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Lupus Nephritis, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Lupus Nephritis, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Lupus Nephritis, 2023
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook